HDP-101 clinical trial in Europe and US continues with adjusted protocol and dose optimization on track; sixth patient cohort dosed at 90 µg/kg and patients are still on treatment Sale of a portion of future royalties for TLX250-CDx to HealthCare Royalty New clinical data with HDP-101 presented at the International Myeloma Society (IMS) Annual meeting; […]
Data from the study with the lead ADC candidate, HDP-101, show elimination of tumor cells in one patient Clinical data from IMS will be presented in R&D webinar on 15 October at 17:00 CEST / 11:00 EDT Ladenburg, Germany, 1 October 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today […]
Ladenburg, Germany, 23 May 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that its management team will be participating and presenting on its proprietary ADC technology platforms at the following scientific conferences in May and June in 2024. Read more…
First efficacy data from the clinical trial with HDP-101 in multiple myeloma Professor Andreas Pahl becomes Chief Executive Officer Successful financing activities Sale of a portion of future royalties for Zircaix™ to HealthCare Royalty finances further development of the ADC pipeline Ladenburg, Germany, 25 April 2024 – Heidelberg Pharma AG (FSE: HPHA) today reported on the […]
Ladenburg, Germany, 5 April 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that it will be hosting an R&D Webinar on 23 April 2024 at 16.00 CEST/15.00 BST, for investors, analysts and media. The R&D webinar will feature presentations from Heidelberg Pharma’s management […]
